Marker Therapeutics (MRKR) Cash from Discontinued Operations (2022 - 2023)

Marker Therapeutics (MRKR) reported Cash from Discontinued Operations of 62938.0 for Q4 2023, up 97.14% year-over-year from 31925.3 in Q4 2022, and up 75.82% quarter-over-quarter from 260281.0 in Q3 2023.

Marker Therapeutics (MRKR) Cash from Discontinued Operations (2022 - 2023) Analysis & Trends

Marker Therapeutics (MRKR) has 2 years of Cash from Discontinued Operations data on file, last reported at 62938.0 in Q4 2023.

  • Cash from Discontinued Operations for Q4 2023 came in at 62938.0, up 97.14% year-over-year; the trailing twelve-month figure through Dec 2023 was 6098899.0 (changed N/A YoY), and the FY2023 annual result was 6098899.0, down 11.73% from the prior year.
  • Cash from Discontinued Operations improved to 62938.0 in Q4 2023 per MRKR's latest filing, from 260281.0 in the prior quarter.
  • Over five years, Cash from Discontinued Operations peaked at 62938.0 in Q4 2023 and troughed at 2985556.0 in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discont. Ops (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - -
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn -
9 Abivax 94.37 Bn 94.37 Bn - -59.14 Mn
10 Marker Therapeutics 28.20 Mn 28.20 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 -62,938.00
Dec 31, 2023 -62,938.00
Sep 30, 2023 -260,281.00
Sep 30, 2023 -260,281.00
Jun 30, 2023 -2.99 Mn
Jun 30, 2023 -2.99 Mn
Mar 31, 2023 -2.79 Mn
Mar 31, 2023 -2.79 Mn
Dec 31, 2022 -2.20 Mn
Dec 31, 2022 -2.20 Mn
Sep 30, 2022 -2.40 Mn
Sep 30, 2022 -2.40 Mn